Merck opens S$20M lab in Sin­ga­pore

BioSpectrum (Asia) - - Company -

Ger­man bio­phar­ma­ceu­ti­cal com­pany Merck has of­fi­cially opened a S$20 mil­lion lab near Pasir Pan­jang, Sin­ga­pore. The Merck Sin­ga­pore Lab of­fers ser­vices such as cell cul­ture me­dia de­vel­op­ment, pu­rifi­ca­tion process op­ti­mi­sa­tion and bi­o­log­ics drug safety test­ing.

The 3,800 sq m fa­cil­ity will also house Merck’s first BioReliance lab­o­ra­tory in the re­gion, to pro­vide phar­ma­ceu­ti­cal firms in Asia with quicker, more ac­ces­si­ble test­ing ser­vices for bi­o­log­i­cal drug prod­ucts. The new lab of­fers con­sumers the as­sur­ance of more speed­ily avail­able and val­i­dated next-gen­er­a­tion drugs for treat­ment. Time taken to val­i­date crit­i­cal pro­cesses, test and re­lease a drug to mar­ket will be sig­nif­i­cantly re­duced. Ac­cord­ing to Dr Koh Poh Koon, Se­nior Min­is­ter of State for Trade and In­dus­try, Merck’s in­vest­ment in Sin­ga­pore is timely as global and re­gional health­care de­mands con­tinue to grow. The Govern­ment has in­vested in in­fra­struc­ture, tech­nol­ogy and tal­ent to help pro­pel the in­dus­try’s growth and will con­tinue to do so.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.